• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A reality check of the accelerated approval of immune-checkpoint inhibitors.

作者信息

Gill Jennifer, Prasad Vinay

机构信息

Division of Hematology Oncology, Oregon Health & Science University, Portland, OR, USA.

Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.

出版信息

Nat Rev Clin Oncol. 2019 Nov;16(11):656-658. doi: 10.1038/s41571-019-0260-y. Epub 2019 Aug 5.

DOI:10.1038/s41571-019-0260-y
PMID:31383994
Abstract
摘要

相似文献

1
A reality check of the accelerated approval of immune-checkpoint inhibitors.免疫检查点抑制剂加速批准的现实审视。
Nat Rev Clin Oncol. 2019 Nov;16(11):656-658. doi: 10.1038/s41571-019-0260-y. Epub 2019 Aug 5.
2
Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective.从全球监管视角看新型肿瘤免疫检查点抑制剂的临床研发和首次批准
Clin Pharmacol Ther. 2019 Mar;105(3):582-597. doi: 10.1002/cpt.1123. Epub 2018 Sep 12.
3
Acquired Resistance to Immune Checkpoint Inhibitors.获得性免疫检查点抑制剂耐药。
Cancer Cell. 2020 Apr 13;37(4):443-455. doi: 10.1016/j.ccell.2020.03.017.
4
Setting the scene - a future 'epidemic' of immune-related adverse events in association with checkpoint inhibitor therapy.背景介绍——免疫相关不良事件伴随检查点抑制剂治疗的未来“流行”。
Rheumatology (Oxford). 2019 Dec 1;58(Suppl 7):vii1-vii6. doi: 10.1093/rheumatology/kez402.
5
Progresses in immunotherapy.免疫疗法的进展。
Int Rev Immunol. 2020;39(5):203-204. doi: 10.1080/08830185.2020.1815444.
6
Principles of Immunotherapy in Melanoma.黑色素瘤的免疫治疗原则。
Surg Clin North Am. 2020 Feb;100(1):161-173. doi: 10.1016/j.suc.2019.09.009. Epub 2019 Nov 1.
7
Intravesical Therapy for Nonmuscle Invasive Bladder Cancer: Twenty-First Century Edition.非肌层浸润性膀胱癌的膀胱内治疗：21世纪版
Urol Clin North Am. 2020 Feb;47(1):xiii. doi: 10.1016/j.ucl.2019.10.001.
8
Keeping Expectations in Check With Immune Checkpoint Inhibitors.用免疫检查点抑制剂控制期望。
J Clin Oncol. 2018 Jun 10;36(17):1654-1657. doi: 10.1200/JCO.2017.76.2146. Epub 2018 Jan 25.
9
Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.免疫检查点抑制剂治疗癌症时免疫相关不良事件的发生机制。
Rheumatology (Oxford). 2019 Dec 1;58(Suppl 7):vii59-vii67. doi: 10.1093/rheumatology/kez308.
10
Check point inhibitors and autoimmunity: Why endocrinopathies and who is prone to?检查点抑制剂与自身免疫：为何内分泌疾病与哪些人易患？
Best Pract Res Clin Endocrinol Metab. 2020 Jan;34(1):101411. doi: 10.1016/j.beem.2020.101411. Epub 2020 Mar 5.

引用本文的文献

1
: A Neurodevelopmental Factor Regulating Cell Metabolism in the Tumor Microenvironment.一种调节肿瘤微环境中细胞代谢的神经发育因子。
Biomolecules. 2025 May 28;15(6):779. doi: 10.3390/biom15060779.
2
Disparities in the access to immune checkpoint inhibitors approved in the United States, the European Union and mainland China: a serial cross-sectional study.美国、欧盟和中国大陆获批的免疫检查点抑制剂可及性差异：一项系列横断面研究
BMJ Public Health. 2025 Mar 13;3(1):e001995. doi: 10.1136/bmjph-2024-001995. eCollection 2025 Jan.
3
Molecular and immunological features associated with long-term benefits in metastatic NSCLC patients undergoing immune checkpoint blockade.
与接受免疫检查点阻断治疗的转移性非小细胞肺癌患者长期获益相关的分子和免疫特征。
Oncoimmunology. 2025 Dec;14(1):2469377. doi: 10.1080/2162402X.2025.2469377. Epub 2025 Feb 24.
4
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment.肿瘤微环境中T细胞麻痹的趋同诱导因子和效应因子。
Nat Rev Cancer. 2025 Jan;25(1):41-58. doi: 10.1038/s41568-024-00761-z. Epub 2024 Oct 24.
5
Criteria for assessing evidence for biomarker-targeted therapies in rare cancers-an extrapolation framework.评估罕见癌症中生物标志物靶向治疗证据的标准——一种外推框架。
Ther Adv Med Oncol. 2024 Sep 2;16:17588359241273062. doi: 10.1177/17588359241273062. eCollection 2024.
6
A general pHLA-CD80 scaffold fusion protein to promote efficient antigen-specific T cell-based immunotherapy.一种通用的pHLA-CD80支架融合蛋白，用于促进基于高效抗原特异性T细胞的免疫疗法。
Mol Ther Oncol. 2024 Jun 10;32(3):200827. doi: 10.1016/j.omton.2024.200827. eCollection 2024 Sep 19.
7
Detection and evaluation of signals for immune-related adverse events: a nationwide, population-based study.免疫相关不良事件信号的检测与评估：一项基于全国人群的研究。
Front Oncol. 2024 Jan 26;13:1295923. doi: 10.3389/fonc.2023.1295923. eCollection 2023.
8
Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram.利用新型且经外部验证的预后列线图，完善下一代免疫治疗早期临床试验的患者选择。
Front Immunol. 2024 Jan 15;15:1323151. doi: 10.3389/fimmu.2024.1323151. eCollection 2024.
9
Key Determinants of Immune-Mediated Adverse Reactions to Oncology Drugs.肿瘤药物免疫介导不良反应的关键决定因素。
Cancers (Basel). 2023 Nov 28;15(23):5622. doi: 10.3390/cancers15235622.
10
Serum sodium levels associate with recovery of kidney function in immune checkpoint inhibitor nephrotoxicity.血清钠水平与免疫检查点抑制剂肾毒性中肾功能的恢复相关。
Front Med (Lausanne). 2023 Jul 20;10:1020691. doi: 10.3389/fmed.2023.1020691. eCollection 2023.